Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)

• Company Description    AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $20.88 Daily Weekly Monthly 20 Day Moving Average: 476,832 shares Shares Outstanding: 28.19 (millions) Market Capitalization: $588.53 (millions) Beta: 0.17 52 Week High: $37.89 52 Week Low: $19.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.56% 3.40% 12 Week -33.57% -25.34% Year To Date -39.91% -26.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10770 WATERIDGE CIRCLE SUITE 210 - SAN DIEGO,CA 92121 USA ph: 858-362-6295 fax: - investors@anaptysbio.com http://www.anaptysbio.com

• General Corporate Information    Officers Hamza Suria - Chief Executive Officer and President Dennis Mulroy - Chief Financial Officer Daniel Faga - Director Dennis Fenton - Director Laura J. Hamill - Director Peer Information AnaptysBio, Inc. (CORR.) AnaptysBio, Inc. (RSPI) AnaptysBio, Inc. (CGXP) AnaptysBio, Inc. (BGEN) AnaptysBio, Inc. (GTBP) AnaptysBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032724106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 28.19 Most Recent Split Date: (:1) Beta: 0.17 Market Capitalization: $588.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: 11.13 EPS Growth vs. Year Ago Period: -98.48% vs. Previous Quarter: -15.93% Sales Growth vs. Year Ago Period: -91.38% vs. Previous Quarter: -4.06% ROE 03/31/22 - -20.44 12/31/21 - -14.95 09/30/21 - 2.17 ROA 03/31/22 - -14.05 12/31/21 - -11.92 09/30/21 - 2.02 Current Ratio 03/31/22 - 25.90 12/31/21 - 34.40 09/30/21 - 18.51 Quick Ratio 03/31/22 - 25.90 12/31/21 - 34.40 09/30/21 - 18.51 Operating Margin 03/31/22 - -140.72 12/31/21 - -89.19 09/30/21 - 6.87 Net Margin 03/31/22 - -143.46 12/31/21 - -91.49 09/30/21 - 6.87 Pre-Tax Margin 03/31/22 - -143.46 12/31/21 - -91.49 09/30/21 - 6.87 Book Value 03/31/22 - 11.73 12/31/21 - 12.89 09/30/21 - 13.98 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©